Article
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Cancer chemotherapy and pharmacology - 1 Mar 2012
Mazard T, Ychou M, Thezenas S, Poujol S, Pinguet F, Thirion A, Bleuse J P, Portales F, Samalin E, Assenat E
Abstract excerpt
BACKGROUND: Biweekly schedule of capecitabine combined with irinotecan (XELIRI), consecutively with irinotecan and oxaliplatin (XELIRINOX), was evaluated in patients with metastatic cancer from any solid tumors. PATIENTS AND METHODS: In this two-step phase I trial, seventeen and eleven patients were enrolled in the XELIRI and XELIRINOX stages, respectively. RESULTS: In XELIRI, a total of 136 chemotherapy cycles...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.